Lupus Therapeutics Market Size, Industry Analysis Report, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI1874
Lupus Therapeutics Market size is projected to experience significant growth from 2017 to 2024.
Rising incidence of lupus around the globe and a strong pipeline of various newer therapeutics will drive lupus therapeutics market growth. It is autoimmune disease that arise when the patients’ immune system attacks their own body. There are several types of known genetic variations related to the disease. Genetics play a significant role in disease development. Huge significant unmet needs and increase in available therapeutic options for patients with potent clinical benefits will fuel the treatment demand.
Increasing amount of funding and public-private initiatives to generate public awareness will provide significant growth opportunity. The major restraint for the industry is difficulty in identifying a lupus, since its symptoms mimic several other illnesses. Lack of reimbursement in developing economies may also hinder the lupus therapeutic market growth over the forecast period.
Systemic lupus erythematosus market will grow at lucrative rate in the coming years. It affects major tissue or organ in body such as brain, kidneys, heart, or lungs. Lupus nephritis an inflammation of the kidneys can disturb the body’s capability to filter waste from the blood and may require dialysis or kidney transplant. Discoid (Cutaneous) lupus is limited to skin only and characterized by rashes or sores on skin in various body parts like face, neck, in the mouth, nose, and vagina.
Drug-induced Lupus (DIL) is caused due to prescription of certain drugs. Most commonly linked drugs with DIL are procainamide, prescribed for treatment of uneven heart rhythms; hydralazine, prescribed for treatment for hypertension; and isoniazid, prescribed for treatment for tuberculosis. However, not everyone who take these drugs will develop DIL.
Various medications are prescribed for the disease management depending on severity and type of the disease. These medications can range from drug class like non-steroidal anti-inflammatory drugs (NSAIDS), anti-inflammatory drugs, antimalarial drugs, corticosteroids, immunosuppressive drugs anticoagulants and monoclonal antibodies. Ongoing research and recent approvals from FDA will boost the lupus therapeutics market by 2024. The drugs prescribed for therapeutics can be easily obtained from hospitals, retail pharmacies, ambulatory surgical centers, and online pharmacies. Hospitals, followed by retail pharmacies will account for major industry revenue share.
Presence of established infrastructure, sophisticated diagnosis and healthcare facilities will have significant impact on the U.S. lupus therapeutic market growth. According to Lupus Foundation of America, over 1 million people affected by the disease in U.S. alone.
Europe lupus therapeutic market is likely to account for second largest revenue share. Increasing R&D and favorable growth opportunities for companies in the region will drive the market demand. Asia Pacific will rise at comparatively faster rate than developed regions. India and China are two lively regions for business growth. India is likely to exhibit the highest CAGR till 2024 owing to growing number public and private initiatives in the region.
Companies operating in lupus therapeutic market include GlaxoSmithKline, ImmuPharma, Merck, Amgen, Sanofi, Pharmaceutical Industries, Eli Lilly and company, Novartis, Bristol-Myers Squibb, Anthera, Zydus Cadila, Horizon Pharma, and Jubilant Cadista. Collaboration with domestic companies, merger and acquisitions and new product launches are generally preferred policies adopted by the industry players.
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.